Drugs / CLATURAFENIB
CLATURAFENIB
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07563894 | Apr → Jun 2026 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05538130 | Nov 2022 → Aug 2027 expected | brain neoplasm, differentiated thyroid carcinoma, low grade glioma, malignant glioma +2 | Pfizer | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05355701 | Jul 2022 → Aug 2027 expected | colorectal cancer, glioma, melanoma, non-small cell lung carcinoma +1 | Pfizer | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CLATURAFENIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068425 ↗ |
| Known as | ARRY-440 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068425 ↗ |
| Known as | PF-07799933 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07563894 ↗ |
| Modality | Small molecule | — CHEMBL6068425 ↗ |
| Route | Oral | “PF-07799933 comes as a tablet to take by mouth, 2 times a day.” NCT05355701 ↗ |